

# MMV's Drug Discovery Project: Test Cascade Towards the Development of New Antimalarials

Luiz Carlos Dias <sup>1</sup> Dominique Soldati-Favre <sup>2</sup> Mariana Ferrer Casal <sup>3</sup> Anees Ahmad <sup>3</sup> Anwar Shamim <sup>3</sup> Anna Caroline Aguiar <sup>4</sup> Sarah El Chamy Maluf <sup>4</sup> Guilherme Souza <sup>4</sup> Rafael V <sup>5</sup> Tom Tom Vongeldern <sup>6</sup> Delphine Baud <sup>6</sup> Paul Willis <sup>6</sup>  
Vol 1, 2022 - 153219  
Poster

## Abstract

As a part of Medicines for Malaria Venture's efforts to deliver a clinical candidate that could be used as a Single Encounter Radical Cure and Prophylaxis (SERCaP) for Malaria, several compound libraries were screened against Plasmodium falciparum. The Screening Actives were prioritized based on their potency, physicochemical properties, and structural alerts. Then, top prioritized compounds were resynthesized or purchased to confirm the activity against P falciparum.

Once the activity of the Screening Actives is confirmed, the Hit Compounds are profiled in depth, to prioritize work on series that are more likely to progress to Lead Optimization Stage. For instance, throughout our work we found that besides testing the compounds against sensitive and resistant strains, we should also evaluate the propensity of generating resistance by determining the Minimum Inoculum for Resistance. Herein, we will present some of our progress towards the Validation of Hit Compounds.

Share your ideas or questions with the authors!



Did you know that the greatest stimulus in scientific and cultural development is curiosity? Leave your questions or suggestions to the author!

Sign in to interact

## Institutions

- <sup>1</sup> UNICAMP
- <sup>2</sup> Medicines for Malaria Venture
- <sup>3</sup> Universidade Estadual de Campinas
- <sup>4</sup> USP - São Carlos
- <sup>5</sup> Universidade de São Paulo
- <sup>6</sup> MMV

## Keywords

- Drug Discovery
- Drug Development
- hit validation
- malária
- SAR exploration